Emerging data suggest Retatrutide , a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could provide a promising advancement for weight treatment. Early human trials have indicated considerable losses in body fat , potentially exceeding existing weight-loss medications . Nevertheless , further assessment is re